you, be Thank to here. Hi, everyone. great Josh. It's
Tesla And some the of side that. you from know sell Axon me before may or or
OncoCyte help mission, company. joined team. the X and primary to build strategy As to said, OncoCyte: drew that scale me and I factors There timing, Josh were
save Axon, lives. me and First, here what reminds the is is of attractive, which mission to we had at it
very mission presentation You'll we patient notice testing that to outcomes. molecular novel today succinctly access follows: improve we our investor to democratize new diagnostic published as in to synthesized the
market. do We which company to just product have I was do background product commercializing to this tech to I our of with a of it. lot I take company interested care, to health of that is going an it with cusp the a very and history don't in bring to a than finance. it a I and talking in opportunity where was attractive and quite years we on have more commercialization technology spring, with to are Where soon, brings timing. in a When background wasn't me. would development journey behind XX of started good a learned OncoCyte the to My in me our decade
of call who on this for you XX on product. So to those thank years the worked you have
strategy to a to selling of to strategy at that timing, In disruptive attractive I margins highly the is very gross found model addition compelling. diagnostic business much I'm industry. to the the tests be via software-like
and always We that potential do, that is and me and of scale businesses the become asset-light, be can too. my large. appreciated quickly high-margin investor company guess analyst in have has The an quite many to like the that, eventually you
today. to team. the drawn we our I quality in on This Schütz, cell-free world-class including test the was expect who enjoy to products, and developing IP of scientists products have margins. Chief will support compelling world-renowned having the obtaining approval Officer, expertise immuno-oncology DNA extensive sell with These diagnostic is We scientists that company, experience Ekke created Dr. has line Science this developing regulatory Third, kits.
with Riggs, make high The years easy, California, admire It of here and a that be already Irvine, smarts, a the me financial the decisions has combination in been a a company's exhibits ability degree culture who He clarity. clear into stepping grit. a to not expert. to CFO pivot important helps subject discipline. and is beside I strong integrity matter sitting of past is Josh over also few deep enjoys
I born remain fiscal support of it it muscle of course, operating That partnership. leverage. great this knew was will discipline a necessity, but and be that Of will could strong, future
Okay.
punches above weight. team the the So and their strategy sense makes
this that Now the will point saw a I the early company to of that question how X is, in things play strategy success. innings potentially out? is
of we sales without proactively we from pretty muscle transplant First, sales amazing research is fit. diagnostic gaining great access can centers great already invest us, to out and even interest OncoCyte get GraftAssure faster. and The wouldn't the are with indications if we is to product have are it that more exciting. market that to What's reach go reaching forward be in
third, focusing clear Second, many It the with big XXXX most investor. This is validation publication which to adds second the winner. prebuilt to clear be the that really, a a of in recent of need it has potential me the strategic scalable, on is that deal. a into high-margin the and partner points, selling Journal proof investment really England is was the channel and up May OncoCyte also New And company's big This channels. a to Bio-Rad its is appeared partnership largest product Medicine. fills of scientific
be in wide clear, I with to came also open. eyes Now
their some volume we the is balance true and while a impressed company, we investors is team company and the with also of weak I small, our management While and the was and I the I are knew still trading was that sheet. of support, aware it in have Board, tiny strong a
was All solvable. of this
we them prior background this include: the characteristics provide my to the companies What characteristics. compelling that These proposition money clear where and fast and investors will to opportunities, to retire certain customer with move is value ability and market, a was capture in is also and from ability me the are. manage to risks
a In the large. over to we market years test the the into next capture market. opportunity selling The diagnostic transplant term, have to by very near X opportunity is biomarker X share known the
is or period, as not We potential unreasonable timeframe, also Tesla compelling $X I focused over the a Axon. is period here. to companies such am have I've could the why opportunity on X- become with which that XX-year company. that Over it a always is That billion we
We well and eager as it to compelling guide I'm have tell story help it. tell, a to as
this shareholder telling story, can report, far As earnings letter. are that as that with we you see introducing a
We kits versus why we a investor publishing lab deck that test in in in-house are molecular are developing also clinical testing and model. diagnostic new developing explains investing specifically an
projected these get excited revenue XXXX sending we customer are build and to presented a tests about is FDA that the to that In the so that bringing understand out patient up speak. In for transplant graphic are product materials, online their in-house. sell late eventually clinical populations center an assumes customers intended switches managing we to approval we a show assumes in IVD we from we why their we that as our beta graphic, you
a and do why from important is it because disclaimer view forward-looking are sit no where felt on our Now we that we building that we there's we to also was there of all what today. guarantees. projections, a statement are share reason But
count transparent can on risks. You journey. And the about growth transparency us not that about also only to but the on opportunities, our includes be
shareholder a reported and This that the market our The in had very our opportunity first in would capital market others existing highlight tables of need they're markets to read was fund me to you that warrant numbers with fact go was real Bio-Rad, we don't the investors, coverage no raise that is and for done we the see and have partner, that off quarter, you. are after, We discounts. including I to new letter, As for and the thing at no successful. participation from it April one and to starting in corporate speaks opportunity. the
point. preferred inflection today, thank does structure me and I'd now including redemptions and joining We community, partnership hit look capital and stock so to more shareholders, preferred no our as which also as just investment we much streamlined an truly we common you the as enjoy welcoming investors or hopefully time we in with for highlight grow. that the it stock, over our excites April, a stock analysts and relationship we with with value you debt forward as
be that and which with opportunity face that capital we we steadily exciting. derisked. think revenue, high our pass-through being leverage the The business revenue are the set day, by is light. is Day we both you'll capturing Once margin itself, is pleased in gross model
Okay.
So any your we now ahead, we questions. Go welcome Do Jeff. have queue? questions in the
